NEOMYCIN
Inflammatory Bowel Disease (IBD)
Assistance Publique - Hôpitaux de ParismixturePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Inflammatory Bowel Disease (IBD) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bacitracin Assistance Publique - Hôpitaux de Paris | Phase 2 | CCC |
Colon Kcc Heptapeptide Danielle Kim Turgeon | Phase 1 | CC |
Same molecule, other indications
NEOMYCIN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →